Paclitaxel CAS：33069-62-4

Mechanism of Action: This therapeutic agent specifically attaches to assembled microtubules, promoting their stability and thereby interfering with normal cell division processes.

Oncologic Efficacy: Clinically proven effective against a range of cancers, including ovarian, breast, non-small cell lung, colorectal, and other solid tumors.

Cell Cycle Disruption: Triggers cell cycle arrest precisely during mitosis, thereby suppressing malignant cell proliferation and tumor growth.

Clinical Evidence: Widely utilized in advanced cancer treatment regimens, with robust efficacy data supported by Phase II and Phase III clinical trials.